Member Info for Brand

Just popping in to tap the sign.

This Orchestrated Conversation is to distract you from the information shared in the first post and to ensure a genuine conversation regarding its contents doesn't ensue.

Also curious if we are due a TR-1 any time soon.

Seems like a good time to highlight this one, published just a couple weeks ago

https://www.nature.com/articles/s12276-023-00964-8

Lmao

Looks like it could be a meta analysis of sng001 vs covid

I know this board loves a SPAC chat

https://www.fiercebiotech.com/biotech/spacs-back-brink-nk-focused-biotechs-plans-blank-check-merger

"and we are bringing together a unique consortium of companies willing to work pre-competitively to understand more about this challenge to health.”

So what does this mean?

This gentleman looks to have received a grant to run the trial - effective Jan 23

https://kirby.unsw.edu.au/people/associate-professor-stuart-turville

Australian winter starts June 21st

https://www.gov.uk/government/news/mhra-to-receive-10m-from-hm-treasury-to-fast-track-patient-access-to-cutting-edge-medical-products

"The funding over the next two years will support development of a thorough but shortened process to speed up the approval process for cutting-edge treatments developed in the UK with the greatest opportunity to meet the UK’s healthcare priorities, such as cancer vaccines and AI-based therapeutics for mental ill-health."

https://www.ft.com/content/ff254600-1f51-469b-be4b-b46e868eaf9b

"The UK’s biotech companies are among the winners under the new slimmed-down tax credit scheme because they tend to spend more on R&D than tech start-ups. Hunt gave the example of a cancer drug company spending £2mn on R&D, which would receive more than £500,000 in tax credits."

https://www.bioindustry.org/news-listing/chancellor-gives-boost-to-medical-innovation-and-life-sciences-industry-in-spring-budget.html

"The new R&D-intensive company category is a highly effective way to incentivise truly innovative businesses taking significant financial risk by investing heavily in R&D. It will target UK taxpayer support to enable life science entrepreneurs to crowd in further private investment allowing them to grow and accelerate innovation in the UK."

https://www.reuters.com/world/uk/new-tax-credit-scheme-lifeline-british-biotech-say-execs-2023-03-15/

LONDON, March 15 (Reuters) - Britain's budget has offered a shot in the arm to research-intensive biotech and life-sciences sector, company executives said on Wednesday, as the government seeks to put the industry in the global vanguard.
Finance minister Jeremy Hunt said if 40% or more of expenditure of small and medium-sized enterprises (SMEs) was on research and development (R&D) and they were not yet profitable, they could claim credit of 27 pounds ($33 ) per 100.

The announcement was met with considerable relief by small drug developers who can take years, typically spending millions, before ever seeing a medicine hit the market.

The new credit scheme goes a long way to quell the concern around lowering of some R&D tax relief for SMEs announced last October, said Kevin Pojasek, CEO of Oxford-based Enara Bio.

It should also encourage investors who will see more value for their money

"The research and development tax credit increased from £3.8 million to £9.2 million on account of the increased qualifying project expenditure, primarily on the SPRINTER trial and manufacturing development activities. The credit equates to 17% of our 2021 research and development expenditure (2020: 25%). "

https://endpts.com/uk-rd-credit-increase-faster-drug-approvals-promised-in-budget-speech/

But Hunt, the former UK health secretary, said today in his Spring 2023 budget speech that he had returned with a “more robust” R&D tax credit scheme.

Part of that is an “enhanced credit” for qualifying small or medium-sized biopharma businesses. If a company spends 40% or more of its total expenditure on R&D, it can claim a credit worth £27 for every £100 they spend, as well as a £1.8 billion support package for 20,000 companies.

It's funny the original thread w this subject seems to be full of accounts fighting each other. I wonder why.

Anyway I know the company claimed a significant amount in r&d tax credit in the last fiscal year. In theory it should cover a significant portion of any new trials the company undertakes.

It seems like while I personally think the Tories are well past their best before date, at least there are grown ups in charge.

Would be pretty funny if Jeremy Hunt blew up someone's short play ;-)

Like moths to a flame...

Can only be a good thing...

https://www.sciencemediacentre.org/expert-reaction-to-the-spring-budget-2/
Steve Bates OBE, CEO of the UK BioIndustry Association (BIA), said:

“An enhanced tax relief for R&D-intensive SMEs is a huge boost for biotech companies across the UK developing new medicines and improving healthcare for patients. Our research intensive industry is a key growth area for Britain’s economy. The Chancellor is rightly focusing UK taxpayer support to enable life science entrepreneurs to crowd in more private investment, help keep the UK at the cutting-edge of international science, and create new high value jobs across the UK.”

Given the authors of the paper - the who very much looks to be the CCP. The why, probably not as easy to answer.

Re DDs comment. The CCP are certainly interested in covid

Seems like it could be quite relevant...

https://www.medrxiv.org/content/10.1101/2023.03.06.23286834v1

BeBold,

TW is/was lead investigator on SNG sponsored trials - if you have a look back through RNSs, protocols etc you'll often see his name at the top.

A simple "Tom Wilkinson Synairgen" search on Google should paint the picture for you.

As TW has been leading so much of the companies work over the last years, I think it's fair to say this recognition from NIHR is very noteworthy.